ClinicalTrials.gg
CompletedNCT06160895Updated Oct 30, 2024

A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects

A Phase 1 interventional study of TQ-A3334 tablets and TQ-A3334 placebo tablets in Hepatitis B, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-30.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 192 studies in Hepatitis B with a site in China — 39 open to participants now, 49 under way, 1 of them phase 3. Hepatitis B · China.

Enrollment
115th of 136
40 · median 123
Started
2023
with 4 others
Phase 1
19 of 192
7 open now
Registered
161st of 192
by date

Among the 192 studies in Hepatitis B with a site in China, this one is the 115th largest by enrollment of the 136 interventional ones that give a count, is one of 5 that started in 2023, is one of 19 in phase 1, and was the 161st registered.

Hepatitis B

1,047 studies on the registry are indexed under Hepatitis B; 140 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

39 of the 192 studies in Hepatitis B with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 192 studies in Hepatitis B with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled Phase I clinical study of TQ-A3334 tablets in adult healthy subjects, and the trial is planned to enroll 60 healthy subjects.

The primary objective is to evaluate the safety and tolerability of multiple dosing of TQ-A3334 tablets in healthy subjects.

03

Conditions studied

  • Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign the form before the study, and fully understand the study content, process and possible adverse events;
  • Be able to complete the study according to the requirements of the protocol;
  • Male and female subjects aged 18 to 55 years (inclusive);
  • Male subjects weigh not less than 50 kg, female subjects weigh not less than 45 kg, (BMI) in the range of 18 \~ 28 kg/m2 (inclusive);
  • No medical history of cardiac, hepatic, renal, gastrointestinal, neurological, respiratory, psychiatric abnormalities and metabolic abnormalities;
  • Subjects (including partners) are willing to voluntarily take effective within 2 weeks before screening to 6 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are breastfeeding or plan to conceive or have a positive serum pregnancy results during the screening or study period;
  • A pre-existing or current neuropsychiatric, respiratory, cardiovascular, gastrointestinal, hematologic-lymphatic, hepatic or renal insufficiency, endocrine, or musculoskeletal disease or other condition which, in the judgment of the Investigator, may have an effect on drug metabolism or safety;
  • Eye diseases, including fundus lesions;
  • History of infections, including upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTI), requiring antibiotic or antiviral medication within 14 days prior to screening or during screening;
  • Acute illness or concomitant medication from the screening phase until study drug administration;
  • History of dysphagia or any gastrointestinal disorder that interferes with drug absorption;
  • Abnormal and clinically significant findings on vital signs, physical examination, laboratory tests, 12-lead , abdominal ultrasound, and chest radiographs during the screening period;
  • Positive for in Hepatitis B, , Syphilis, and (HIV) antigen/antibody;
  • Have taken any medication that can alter liver drug enzyme activity within 28 days prior to screening;
  • Received immunoglobulin or blood product therapy within 30 days prior to screening;
  • Have taken an drug or participated in a clinical trial of any drug within 3 months prior to screening;
  • Have taken Any prescription, over-the-counter, vitamin product, or herbal medication within 2 weeks prior to screening;
  • Use of any systemic cytotoxic or systemic drug within 6 months prior to screening or during the study period, or use of any localized cytotoxic or localized immunosuppressive drug within 30 days or 5 half-lives, whichever is longer, prior to screening or during the study period;
  • Have undergone surgery within 4 weeks prior to screening or who plan to undergo surgery during the study period;
  • Have lost blood or donated more than 400 mL of blood within 2 months prior to screening;
  • Potential blood collection difficulties, history of needle and blood sickness;
  • Having any clear history of drug or food allergy, especially to ingredients similar to those of the study drug;
  • Those who smoked more than 5 cigarettes/day or used an equivalent amount of nicotine or nicotine-containing products within 3 months prior to screening, or who were unable to discontinue the use of any tobacco-based products during the trial;
  • Those who have a history of chronic alcohol abuse or who have consumed more than 14 units of alcohol per week within 3 months prior to screening or who are unable to abstain from alcohol for the duration of the test or who have a positive breathalyzer test for alcohol;
  • Those with a history of drug abuse or a positive urine drug screen;
  • Those who can not avoid xanthine-rich beverages or foods or other factors that may affect drug absorption, distribution, metabolism, excretion, etc., from at least 1 day prior to study dosing until the end of the study;
  • Subjects who, in the opinion of the investigator, have other factors that were unsuitable for participation in this trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    TQ-A3334 tablets (once a day)

    TQ-A3334 tablets, administered once a day.

    Drug: TQ-A3334 tablets

  • Placebo comparator
    TQ-A3334 placebo tablets (once a day)

    TQ-A3334 placebo tablets, administered once a day.

    Drug: TQ-A3334 placebo tablets

  • Experimental
    TQ-A3334 tablets (every other day)

    TQ-A3334 tablets, administered once every other day.

    Drug: TQ-A3334 tablets

  • Placebo comparator
    TQ-A3334 placebo tablets (every other day)

    TQ-A3334 placebo tablets, administered once every other day.

    Drug: TQ-A3334 placebo tablets

  • Experimental
    TQ-A3334 tablets (every three days)

    TQ-A3334 tablets, administered once every three days.

    Drug: TQ-A3334 tablets

  • Placebo comparator
    TQ-A3334 placebo tablets (every three days)

    TQ-A3334 placebo tablets, administered once every three days.

    Drug: TQ-A3334 placebo tablets

Interventions

  • TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.

  • DrugTQ-A3334 placebo tablets

    TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AE)

    Incidence of adverse events (AE) evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.

  2. Severity of adverse events (AE)

    Severity of adverse events (AE) evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.

  3. Incidence of serious adverse events (SAE)

    Incidence of serious adverse events (SAE) evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.

  4. Severity of serious adverse events (SAE)

    Severity of serious adverse events (SAE) evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.

  5. Tolerability after drug administration

    Tolerability is evaluated by the number of participants with abnormal laboratory examinations, vital signs, physical examination, electrocardiogram.

    Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.

Secondary outcomes

  1. Peak Time (Tmax)

    The time required to reach the highest concentration (peak drug concentration) on the human blood concentration curve after administration.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  2. Peak concentration (Cmax)

    The highest blood drug concentration achieved after administration.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  3. Plasma concentration-area under time curve (AUC0-24)

    The area under the plasma concentration-time curve from the beginning of the first administration to 24 hours.

    Time frame: From 60 minutes before administration on Day 1 to 24 hours after the last administration.

  4. Plasma concentration-area under time curve (AUC0-24)

    The area under the plasma concentration-time curve from the beginning of the first administration to the last measurable concentration point.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  5. Plasma concentration-area under time curve (AUC0-∞)

    Extrapolated from the first administration to the area under the plasma concentration-time curve to infinity.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  6. Apparent volume of distribution (Vd/F)

    The ratio of the drug dosage in the body to the blood drug concentration when the drug reaches dynamic equilibrium in the body.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  7. Clearance (CL/F)

    Ratio of drug clearance rate to administration concentration.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  8. Elimination half-life time (t1/2)

    The time it takes to reduce the concentration of drugs in the blood by half

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  9. Time of maximum concentration under steady state (Tmax,ss)

    Time required to reach steady-state peak concentration after administration.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  10. Maximum concentration under steady state (Cmax, ss)

    The highest blood drug concentration that occurs after reaching steady state.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  11. Minimum concentration under steady state (Cmin, ss)

    The lowest blood drug concentration that occurs after reaching steady state.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  12. Plasma concentration at steady state (Cav, SS)

    The plasma concentration at which the rate of administration and rate of elimination are in equilibrium.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  13. Plasma concentration area under steady-state time curve (AUCss)

    The area under the plasma concentration-time curve of the steady state.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  14. Accumulation Index (Rac)

    The ratio of steady-state blood drug concentration to blood drug concentration after the first administration.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  15. Degree of fluctuation (DF)

    The ratio of the difference between the maximum steady-state blood drug concentration and the minimum steady-state blood drug concentration to the average steady-state blood drug concentration.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  16. Interferon-α concentration (IFN-α)

    The change of subjects' blood IFN-α concentration from baseline.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  17. Interferon-stimulated gene concentration (ISG)

    The change of subjects' blood ISG concentration from baseline.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  18. Interferon-gamma concentration (IFN-γ)

    The change of subjects' blood IFN-γ concentration from baseline.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  19. Tumor Necrosis Factor-α concentration (TNF-α)

    The change of subjects' blood TNF-α concentration from baseline.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  20. Interleukin-6 concentration (IL-6)

    The change of subjects' blood IL-6 concentration from baseline.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  21. Interleukin-2 concentration (IL-2)

    The change of subjects' blood IL-2 concentration from baseline.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  22. Monocyte Chemotactic Protein 1 concentration (MCP-1)

    The change of subjects' blood MCP-1 concentration from baseline.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  23. Interferon-inducible protein-10 concentration (IP-10)

    The change of subjects' blood IP-10 concentration from baseline.

    Time frame: From 60 minutes before administration on Day 1 to 72 hours after the last administration.

  24. QT/QT interval

    Level of change in QT/QT interval to evaluate the drug cardiotoxicity.

    Time frame: From 30 minutes before administration on Day 1 to 48 hours after the last administration.

07

Study locations

1 site
  • The first hospital of Jilin University
    Changchun, Jilin 130021, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Jun 2024, 5 months.

Of 49 industry-sponsored phase 1 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 5 months is below that.

Counting every sponsor, half of 58 studies reached it within 14 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2023
First posted
Dec 7, 2023
StartActual
Dec 26, 2023
Primary completionActual
Jun 24, 2024
CompletionActual
Aug 19, 2024
Last update
Oct 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06160895
Responsible party
Sponsor
First posted
Dec 7, 2023
Start date
Dec 26, 2023
Primary completion
Jun 24, 2024
Completion
Aug 19, 2024
Last update
Oct 30, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TLR7 Agonist JNJ-64794964

Start the discussion